AnaptysBio, a clinical-stage biotechnology company, announced a $100 million Stock Repurchase Plan.
The plan allows the company to repurchase up to $100 million of its outstanding common stock.
AnaptysBio anticipates ending 2025 with approximately $300 million in cash, including a $75 million sales milestone from GSK.
Stock Repurchase Plan
AnaptysBio authorized a $100 million Stock Repurchase Plan, in addition to the existing $75 million plan.
Cash Position
Anticipates ending 2025 with about $300 million in cash, including a one-time $75 million milestone in Q4 2025.
Business Focus
AnaptysBio focuses on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases.
- The repurchase plan aims to optimize shareholder value and signal confidence in the company's future.
- Ending 2025 with $300 million in cash enhances financial stability and flexibility for future growth initiatives.
AnaptysBio's Stock Repurchase Plan reflects strategic financial management and confidence in the company's performance and growth trajectory.